Dapoxetine

證據等級: L5

預測適應症: 3 個

Dapoxetine: From Premature Ejaculation to Migraine Disorder

One-Sentence Summary

Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI), currently approved in multiple countries (but not India) for the treatment of premature ejaculation. The TxGNN model predicts it may be effective for Migraine Disorder, with 0 clinical trials and 2 publications (indirect evidence only) currently supporting this direction — primarily through the shared serotonergic mechanism. However, a fundamental pharmacokinetic limitation — Dapoxetine’s ultra-short half-life (~1.5 h) — raises serious doubts about its clinical feasibility for migraine prevention.

Quick Overview

Item	Content
Original Indication	Premature ejaculation
Predicted New Indication	Migraine Disorder
TxGNN Prediction Score	99.34%
Evidence Level	L4 (mechanism/preclinical only)
India Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the standard data source. Based on pharmacological data retrieved from drug interaction databases, Dapoxetine is a short-acting SSRI that selectively inhibits the serotonin reuptake transporter (SERT, encoded by SLC6A4). Unlike conventional antidepressant SSRIs, it has an exceptionally short half-life (~1.5 hours), which is why it was specifically developed for on-demand use in premature ejaculation rather than as a daily therapeutic agent.

Serotonin (5-HT) plays a central role in migraine pathophysiology. The trigeminal vascular system expresses 5-HT₁B/1D receptors — the very targets exploited by triptans, the current standard-of-care for acute migraine. SSRIs increase synaptic 5-HT concentrations and theoretically could modulate cortical spreading depression (CSD) and trigeminal sensitisation, providing a plausible rationale for preventive use. Indeed, longer-acting SSRIs such as fluoxetine and venlafaxine have some evidence for migraine prophylaxis.

However, Dapoxetine’s pharmacokinetics present a fundamental barrier to this repurposing hypothesis. Sustained 5-HT elevation over days to weeks — necessary for meaningful neuroplastic adaptation and stable migraine threshold modulation — cannot be achieved with a drug that is cleared within hours. This distinguishes Dapoxetine sharply from other SSRIs that have been explored in migraine prevention, and is a critical mechanistic mismatch the TxGNN model (which focuses on target-pathway relationships) cannot fully capture.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33998993	2022	Narrative Review	Current Neuropharmacology	Reviews the full landscape of off-label SSRI uses; includes migraine among conditions where SSRIs have been explored — no specific Dapoxetine migraine data
23504864	2013	Observational / Compliance Study	Urologia	Evaluates patient adherence to Dapoxetine for premature ejaculation; confirms SSRI mechanism and tolerability profile — no migraine-related findings

Note: Neither publication provides direct evidence for Dapoxetine in migraine. PMID 33998993 discusses SSRIs as a class; PMID 23504864 addresses the approved indication. These represent indirect, class-level evidence only.

India Market Information

Dapoxetine currently has no registered products in India. The drug is approved in several other markets (including Germany, Austria, Italy, Portugal, Finland, New Zealand, Argentina, Mexico, and the UK under the brand name Priligy), but has not received approval from the US FDA. A completed Phase 3 US trial (NCT00211094) did not lead to FDA approval.

Safety Considerations

Package insert safety data (warnings and contraindications) for the Indian market is unavailable, as the drug is not registered locally. Based on available pharmacological data:

Mechanism-Based Interaction: Dapoxetine inhibits SERT and therefore carries a risk of serotonin syndrome when combined with other serotonergic agents (other SSRIs, SNRIs, MAOIs, triptans, tramadol). This interaction is particularly relevant in the context of migraine treatment, where triptans — also serotonergic — are commonly used.
Class Effect: As an SSRI, Dapoxetine shares class-level risks including nausea, dizziness, and syncope (especially orthostatic), which have been documented in its approved indication.

Please refer to the approved country-of-origin package insert (e.g., Priligy SmPC) for complete warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model correctly identifies the serotonergic mechanistic link between Dapoxetine and migraine, but a critical pharmacokinetic barrier — Dapoxetine’s ultra-short half-life (~1.5 h) — makes it fundamentally unsuitable for the sustained 5-HT modulation required for migraine prevention. Furthermore, the drug is not marketed in India, there are zero supporting clinical trials, and the two retrieved publications provide only indirect, class-level evidence. The evidence base is insufficient and the mechanistic rationale is weak relative to longer-acting SSRIs already explored for migraine prophylaxis.

To proceed (if reconsidered), the following would be needed:

Pharmacokinetic feasibility assessment: Modelling or in vitro data demonstrating whether any modified-release formulation of Dapoxetine could achieve sustained SERT occupancy relevant to migraine prevention
Mechanistic MOA data: Full DrugBank / literature review of Dapoxetine’s receptor binding profile beyond SERT (e.g., any 5-HT₁B/1D activity)
Comparative literature review: Systematic comparison of Dapoxetine vs. long-acting SSRIs in serotonin-mediated migraine mechanisms
Safety interaction profiling: Formal assessment of Dapoxetine + triptan co-administration risk (serotonin syndrome), given migraine patients often use triptans acutely
Regulatory pathway review: If further evidence emerges, an analysis of the registration pathway in India (CDSCO) would be required
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.